Lactic acidemia in infection with human immunodeficiency virus.
Lactic acidosis in patients infected with the human immunodeficiency virus was initially identified as a rare complication of therapy with nucleoside analog reverse transcriptase inhibitors (NRTIs). The only patient group that appears to be at greater risk is pregnant women. More recently, milder elevations in lactate (i.e., lactic acidemia or hyperlactatemia) have been found to be more common and to be associated with numerous illnesses. Mild asymptomatic lactic acidemia is common, but it appears to lead to more severe illness only rarely. This suggests that routine measurement of plasma lactate should be limited to patients with previous acidemia who reinitiate NRTI therapy and to pregnant women. For symptomatic lactic acidemia (generally >5 mmol/L), NRTIs and other antiretroviral therapy should be ceased. Currently, asymptomatic lactic acidemia should not be treated and should not lead to a change in antiretroviral therapy.
Carr
Andrew
A
HIV, Immunology, and Infectious Diseases Clinical Services Unit, St. Vincent's Hospital, Sydney 2010, Australia. acarr@stvincents.com.au
D000140:Acidosis, Lactic / Q000097:blood / Q000453:epidemiology / Q000209:etiology* / Q000628:therapy; D006678:HIV; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D019344:Lactic Acid / Q000097:blood; D017063:Outcome Assessment, Health Care; D018894:Reverse Transcriptase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use
D018894:Reverse Transcriptase Inhibitors; D019344:Lactic Acid